公开(公告)号：US09388215B2

公开(公告)日：2016-07-12

申请号：US14417110

申请日：2014-03-14

申请人： SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.

发明人： Liping Liu ,  Ru Bai

IPC分类号： A61K38/10 ,  C07K7/08 ,  A61P3/08 ,  C07K14/47 ,  C07K7/02 ,  A61K38/00

CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K7/02 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4733 ,  C07K14/4738

摘要： The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

摘要翻译： 本发明提供INGAP和HIP肽的肽和类似物。 肽和类似物可用于治疗各种疾病和病症的方法中。 这些疾病和病症可包括受损的胰腺功能，治疗代谢疾病，例如糖尿病，1型和2型糖尿病，胰岛诱导，扩增和移植增殖，促进神经保护或神经再生，促进肝脏再生或抑制炎症。

公开(公告)号：US20160144054A1

公开(公告)日：2016-05-26

申请号：US15011092

申请日：2016-01-29

申请人： Universitat Leipzig

发明人： Thomas Arendt ,  Uwe Ueberham

IPC分类号： A61K48/00 ,  A61K38/17

CPC分类号： A61K48/0058 ,  A61K38/1709 ,  C07K14/245 ,  C07K14/4738 ,  C12N15/1135 ,  C12N15/635 ,  C12N2310/14

摘要： Described are vectors containing (a) a gene encoding (i) a CDK4/CDK6 inhibitor, preferably p16INK4a, or (ii) an RNA interfering with CDK4 and/or CDK6 expression and/or activity, under the control of an inducible promoter and (b) a gene encoding a transactivator protein for said promoter useful for treating neurodegenerative disorders. These vectors can be transferred into cells where they will exert a protective function to (i) prevent cell death or to (ii) slow down progression of cell death. These vectors can be used in therapeutic applications to prevent neurodegenerative disorders or to slow down their progression with therapeutic efficacy.

摘要翻译： 描述了含有（a）编码（i）CDK4 / CDK6抑制剂，优选p16INK4a的基因或（ii）在诱导型启动子的控制下干扰CDK4和/或CDK6表达和/或活性的RNA的载体和（ b）编码用于治疗神经变性疾病的所述启动子的反式激活蛋白的基因。 这些载体可以转移到细胞中，在那里它们将发挥保护功能，以（i）预防细胞死亡或（ii）减缓细胞死亡的进展。 这些载体可以用于治疗应用以预防神经变性疾病或以治疗功效减缓其进展。

公开(公告)号：US20160068582A1

公开(公告)日：2016-03-10

申请号：US14861923

申请日：2015-09-22

申请人： Trojan Technologies, Ltd.

发明人： Agamemnon Epenetos ,  Christina Kousparou

IPC分类号： C07K14/47 ,  A61K45/06 ,  A61K38/00 ,  C07K14/435 ,  A61K38/17

CPC分类号： C07K14/4738 ,  A61K31/337 ,  A61K31/513 ,  A61K31/555 ,  A61K33/24 ,  A61K38/005 ,  A61K38/1709 ,  A61K38/1767 ,  A61K45/06 ,  A61K47/64 ,  C07K14/43581 ,  C07K2319/10 ,  A61K2300/00

摘要： The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homologue functional fragment thereof; and a second region comprising a translocation factor.

摘要翻译： P21蛋白用作治疗癌症的药物，缀合物包含包含P21蛋白的第一区域或其同源功能片段; 和包含易位因子的第二区域。

公开(公告)号：US09187526B2

公开(公告)日：2015-11-17

申请号：US14182550

申请日：2014-02-18

申请人： Robert J. Hickey ,  Linda H. Malkas

发明人： Robert J. Hickey ,  Linda H. Malkas

IPC分类号： A61K38/03 ,  C07K4/00 ,  C07K7/06 ,  C07K14/47

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/4738

摘要： Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.

摘要翻译： 衍生自增殖细胞核抗原（caPCNA，也称为csPCNA）或来自nmPCNA相互作用蛋白的癌症特异性同种型的肽干扰细胞内蛋白质 - 蛋白质相互作用，从而导致癌症增殖潜力的降低。 这些肽用作治疗组合物以减少癌细胞的增殖并增加现有的化学治疗方法。

公开(公告)号：US20150238519A1

公开(公告)日：2015-08-27

申请号：US14626852

申请日：2015-02-19

申请人： Ratna Chakrabarti ,  Richard Ottman

发明人： Ratna Chakrabarti ,  Richard Ottman

IPC分类号： A61K31/7105 ,  C07K16/18 ,  A61K31/713

CPC分类号： A61K31/7105 ,  A61K31/713 ,  C07K14/4738 ,  C12N15/113 ,  C12N2310/141

摘要： Disclosed herein are compositions and methods for treating cancer involving the targeting of FGD4. Alternatively, methods and compositions involve the administration of certain miRNA sequences. The administration is effective to reduce the conversion of cancer cells to an aggressive phenotype.

摘要翻译： 本文公开了用于治疗涉及FGD4靶向的癌症的组合物和方法。 或者，方法和组合物涉及给予某些miRNA序列。 该药物可有效降低癌细胞转化为侵袭性表型。

公开(公告)号：US20150218243A1

公开(公告)日：2015-08-06

申请号：US14615224

申请日：2015-02-05

申请人： Samsung Electronics Co., Ltd.

发明人： Jung-Hoon Lee ,  Jae Il Lee ,  Eunji Kang ,  Jungmin Lee

IPC分类号： C07K14/47

CPC分类号： C07K14/4738 ,  A61K38/00 ,  C07K14/4703

摘要： A p15 protein variant; a polynucleotide encoding the p15 protein variant; a method for preparing the p15 protein variant; a pharmaceutical composition comprising the p15 protein variant; and a method for preventing and/or treating cancer comprising administering the p15 protein variant to a subject.

摘要翻译： p15蛋白质变体; 编码p15蛋白变体的多核苷酸; 制备p15蛋白变体的方法; 包含该p15蛋白质变体的药物组合物; 以及用于预防和/或治疗癌症的方法，其包括将p15蛋白质变体施用于受试者。

公开(公告)号：US20150185222A1

公开(公告)日：2015-07-02

申请号：US14415090

申请日：2013-07-19

申请人： TORAY INDUSTRIES, INC.

发明人： Takayoshi Ido ,  Fumiyoshi Okano

IPC分类号： G01N33/574 ,  C07K16/18

CPC分类号： G01N33/57496 ,  C07K14/4738 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/56 ,  G01N33/57492 ,  G01N33/6872 ,  G01N2333/4703

摘要： This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a CAPRIN-1-targeting drug to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.

摘要翻译： 本发明提供了一种检测癌症的方法，其特征在于，包括通过抗体 - 抗体反应与具有SEQ ID NO的偶数序列号SEQ ID NO所示的氨基酸序列的CAPRIN-1的抗体的表达， NO：生物样品中序列表中的2〜30; 用于检测癌症的方法，其涉及确定癌症患者样品中CAPRIN-1的存在和量的量，以确定向癌症患者施用CAPRIN-1靶向药物; 以及用于诊断癌症的药物和试剂盒，其包含抗CAPRIN-1抗体。

公开(公告)号：US09066976B2

公开(公告)日：2015-06-30

申请号：US13215085

申请日：2011-08-22

申请人： Dong-Soo Im ,  Cho-Rok Jung ,  Kyung-Sun Hwang ,  Jung Hwa Lim

发明人： Dong-Soo Im ,  Cho-Rok Jung ,  Kyung-Sun Hwang ,  Jung Hwa Lim

IPC分类号： A61K48/00 ,  C07K14/00 ,  C07H21/04 ,  A61K38/53 ,  C07K14/47 ,  C12N9/00 ,  C12N15/85

CPC分类号： A61K48/005 ,  A61K38/53 ,  C07K14/4703 ,  C07K14/4738 ,  C12N9/93 ,  C12N15/1137 ,  C12N15/85 ,  C12N2310/111 ,  C12N2310/14 ,  C12Y603/02019

摘要： The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF-1α which enhances VEGF activation based on the HIF-1α stabilization. The method for regulating UCP activity or level results in the increase or decrease of VHL activity or level, so that it can be applied to the development of an anticancer agent and an angiogenesis inducer.

公开(公告)号：US20150017232A1

公开(公告)日：2015-01-15

申请号：US14493728

申请日：2014-09-23

申请人： APIM THERAPEUTICS AS

发明人： Marit OTTERLEI ,  Per Arne AAS ,  Emadoldin FEYZI

IPC分类号： C07K14/00

CPC分类号： A61K38/1709 ,  A61K38/00 ,  A61K38/16 ,  A61K38/46 ,  A61K45/06 ,  C07K14/00 ,  C07K14/4738 ,  C07K2319/10 ,  C12Y306/03044 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2800/56

摘要： Disclosed is an oligopeptidic compound capable of interacting with proliferating cell nuclear antigen (PCNA), wherein the compound comprises a PCNA interacting motif which is: (SEQ ID NO. 28) [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R]; wherein the oligopeptidic compound has 9-70 subunits and comprises at least one signal sequence, wherein the signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence and wherein in said compound a PCNA interacting motif is N-terminal to a signal sequence. Also disclosed are methods of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy, or a method of treatment of inflammation said method comprising administering the oligopeptidic compound to a subject in need thereof.

摘要翻译： 公开了能够与增殖细胞核抗原（PCNA）相互作用的寡肽化合物，其中所述化合物包含PCNA相互作用基序：（SEQ ID NO.28）[K / R] - [F / Y / W] L / I / V / A / M] - [L / I / V / A / M] - [K / R] 其中所述寡肽化合物具有9-70个亚基并且包含至少一个信号序列，其中所述信号序列是核定位信号序列和/或细胞穿透信号序列，并且其中在所述化合物中，PCNA相互作用基序是N末端 信号序列。 还公开了治疗期望抑制细胞生长的病症或病症的方法，或涉及细胞抑制治疗的治疗方法或治疗炎症的方法，所述方法包括将寡肽化合物施用于受试者 需要。

公开(公告)号：US20140296484A1

公开(公告)日：2014-10-02

申请号：US13940407

申请日：2013-07-12

申请人： University of South Carolina

发明人： Campbell McInnes ,  Shu Liu

IPC分类号： C07K5/11 ,  C07K5/09

CPC分类号： C07K5/1019 ,  C07K5/0202 ,  C07K5/06095 ,  C07K5/0815 ,  C07K14/4738

摘要： Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.

摘要翻译： 已经研究了肽抑制剂与细胞周期蛋白D和细胞周期蛋白A凹槽结合的结构和功能分析，并用于设计提供结构 - 活性关系的基础的肽，具有改进的结合并具有作为化学生物学探针的潜力作为潜在诊断 并且作为治疗包括癌症和炎症在内的增殖性疾病的治疗剂。